Gastroenterology/Bariatrics Clinical Trial - Abbvie - M14-430

Status:

Open (Study open and enrolling)

ClinicalTrials.gov:

NCT03345823

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered Janus kinase 1 inhibitor, in adult participants with Crohn's Disease.

Drug

Drug: Upadacitinib, placebo

Trial Type

Interventional

Age Range

18 years or older

Condition

Weight loss Crohn's Disease

Keywords

Abbvie | Weight loss | Crohn's Disease | upadacitinib